Physician profile
Sofia E Braylovsky
NPI 1760712707
$9,341.27
in general payments reported to CMS, 2019-2025
38 companies · $4,396 in 2025
The $4,396 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,369 · 2022: $842 · 2023: $744 · 2024: $1,991 · 2025: $4,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,701 · Travel and Lodging: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,700.90 |
| Travel and Lodging | $1,429.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,007.98 | 2022-2025 | Synchromedii |
| Abbvie INC. | $1,385.72 | 2021-2025 | |
| Pfizer INC. | $825.87 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $761.17 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $688.24 | 2024-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $506.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $415.20 | 2022 | |
| Eisai INC. | $395.98 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $255.63 | 2024-2025 | |
| Valinor Pharma, LLC | $216.76 | 2024-2025 | Movantik |
| Forte Bio-Pharma LLC | $208.65 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Biogen, INC. | $151.08 | 2021-2025 | Vumerity, Leqembi |
| Boston Scientific Corporation | $150.43 | 2025 | General - Therapies |
| Sk Life Science, INC. | $146.26 | 2021 | |
| Abbott Laboratories | $125.80 | 2024 | Proclaim |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Braylovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.